Skip to main content
Figure 5 | Journal of Translational Medicine

Figure 5

From: Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors

Figure 5

Bevacizumab treatment improved survival and decreased tumor growth in nude mice bearing Tsc2-/- tumors. (a) Average tumor volume over time for bevacizumab and bevacizumab plus rapamycin treated animals. (b) Survival curve for indicated treatment cohorts. Based on survival analysis and comparison of tumor volumes on day 30, bevacizumab improves survival and decreases tumor growth compared to the untreated cohort. Bevacizumab is not as effective as single agent rapamycin in improving survival or decreasing tumor growth. Based on analysis and comparisons of tumor volumes on day 65, bevacizumab in combination with rapamycin provided no improvement over single agent rapamycin treatment.

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us